A Phase 2 and Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2014
At a glance
- Drugs Tivozanib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Acronyms BATON-RCC
- 07 Jun 2017 Biomarkers information updated
- 11 Aug 2014 According to an Aveo Oncology media release, the results of this trial will be presented at the 2014 European Society for Medical Oncology Congress.
- 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.